How valid are animal models to evaluate treatments for pulmonary hypertension?

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 373, Issue 6, 2006, Pages 391-400

  Campian, Maria E ^a   Hardziyenka, Maxim ^a   Michel, Martin C ^a   Tan, Hanno L ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Endothelin; Hypoxia; Monocrotaline; Phosphodiesterase 5; Prostacyclin; Pulmonary hypertension

Indexed keywords

7,8 DIHYDRO 5 [2 [[ALPHA (3 PYRIDYL)BENZYLIDENE]AMINOOXY]ETHYL] 1 NAPHTHYLOXYACETIC ACID; AMLODIPINE; ARGININE; ATRASENTAN; BERAPROST; BOSENTAN; BSF 420627; CALCIUM CHANNEL BLOCKING AGENT; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; IMMUNOSUPPRESSIVE AGENT; MONOCROTALINE; NIFEDIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE V INHIBITOR; PRAVASTATIN; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTACYCLIN SYNTHASE; PROSTANOID; RAPAMYCIN; SILDENAFIL; SIMVASTATIN; SITAXSENTAN; UNINDEXED DRUG; UNIPROST;

ANALYSIS; DISEASE MODEL; DNA MODIFICATION; DRUG ABSORPTION; DRUG EFFECT; DRUG HALF LIFE; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TARGETING; DUCTUS ARTERIOSUS OBLITERATION; GENE TRANSFER; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; HYPOXIA; LUNG EMBOLISM; NONHUMAN; PULMONARY HYPERTENSION; REVIEW; TREATMENT RESPONSE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANOXIA; DISEASE MODELS, ANIMAL; DUCTUS ARTERIOSUS; EMBOLISM; HUMANS; HYPERTENSION, PULMONARY; MONOCROTALINE; POISONS;

EID: 33748753564     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-006-0087-9     Document Type: Review

References (120)

1. Abman SH, Shanley PF, Accurso FJ (1989) Failure of postnatal adaptation of the pulmonary circulation after chronic intrauterine pulmonary hypertension in fetal lambs. J Clin Invest 83:1849-1858
2. Archer SJ, Michelakis ED (2006) An evidence-based approach to the management of pulmonary arterial hypertension. Curr Opin Cardiol 21:385-392
3. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, McLaughlin VV (2004) Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126:35-62
4. Belik J, Halayko AJ, Rao K, Stephens NL (1993) Fetal ductus arteriosus ligation. Pulmonary vascular smooth muscle biochemical and mechanical changes. Circ Res 72:588-596
5. Beppu H, Kawabata M, Hamamoto T, Chytil A, Minowa O, Noda T, Miyazono K (2000) BMP type II receptor is required for gastrulation and early development of mouse embryos. Dev Biol 221:249-258
6. A-receptor antagonist, attenuates hypoxic pulmonary hypertension in rats. Am J Physiol 266:H1327-H1331
7. Bottiger BW, Motsch J, Dorsam J (1996) Inhaled nitric oxide selectively decreases pulmonary artery pressure and pulmonary vascular resistance following acute massive pulmonary microembolism in piglets. Chest 110:1041-1047
8. Bresser P, Fedullo PF, Auger WR, Channick RN, Robbins IM, Kerr KM, Jamieson SW, Rubin LJ (2004) Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Resp J 23:595-600
9. Budts W, Pokreisz P, Nong Z, Van Pelt N, Gillijns H, Gerard R, Lyons R, Collen D, Block KD, Janssen S (2000) Aerosol gene transfer with inducible nitric oxide synthase reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats. Circulation 102:2880-2885
10. Channick RN, Simonneau G, Sitbon O (2001) Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 358:1119-1123
11. Chen S, Chen Y, Meng QC, Durand J, Dicarlo VS, Opari S (1995) Endothelin- receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 79:2122-2131
12. Chen S, Chen Y, Opgenorth TJ, Wessale JL, Meng QC, Durand J, Dicarlo VS, Opari S (1997) The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia- induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats. J Cardiovasc Pharmacol 29:713-725
13. Clozel JP, Saunier C, Hartmann D, Fischli W (1991) Effects of cilazapril, a novel angiotensin converting enzyme inhibitors, on the structure and function of pulmonary arteries of rats expos to chronic hypoxia. J Cardiovasc Pharmacol 17:36-40
14. Dantzker DR, Bower JS (1981) Partial reversibility of chronic pulmonary hypertension caused by pulmonary thromboembolic disease. Am Rev Respir Dis 124:129-131
15. Das S, Kumar N (1995) Nitric oxide: its identity and role in blood pressure control. Life Sci 57:1547-1556
16. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fischer SG, Barst RJ, Hodge SE, Knowles JA (2004) Familial primary pulmonary hypertension (gene PPH1) is caused by mutation in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67:737-744
17. Di Carlo VS, Chen SG, Meng QC, Durand J, Yano M, Chen YF, Oparil S (1995) ETA-receptor antagonist prevents and reverses chronic hypoxia- induced pulmonary hypertension in rat. Am J Physiol 269:L690-L697
18. Dingemanse J, van Giersbergen LM (2004) Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacochinet 43(15):1089-1115
19. Eddahibi S, Raffestin B, Cloze M, Levame M, Adnot S (1995) Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats. Am J Physiol 268:H828-H835
20. Eddahibi S, Hanoun N, Lanfumey L, Lesch KP, Raffestin B, Hamon M, Adnoy S (2000a) Attenuated hypoxic pulmonary hypertension in mice lacking 5-hydroxytryptamine transporter gene. J Clin Invest 105:1555-1562
21. Eddahibi S, Hanoun N, Lanfumey L, Lesch K, Raffestin B, Hamon M, Adnot S (2000b) Attenuated hypoxic pulmonary hypertension in mice lacking the 5- hydroxytriptamine B11transporter gene. J Clin Invest 105:1555-1562
22. Eddahibi S, Humbert M, Fadel E, Raffestestin B, Darmon M, Capron F, Simonneau G, Dartevelle P, Hamon M, Adnoy S (2001) Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 108:1141-1150
23. Faul JL, Nishimura T, Berry GJ, Benson GV, Pearl RG, Kao PN (2000) Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 162:2252-2258
24. Fishman AP (2001) Clinical classification of pulmonary hypertension. Clin Chest Med 22:385-391
25. Fung YC, Lin Q (1991) Changes of zero-stress state of rat pulmonary arteries in hypoxic hypertension. J Appl Physiol 70:2455-2470
26. Galie N, Hossein AG, Torbicki A, Barts RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353:2148-2157
27. Girgis RE, Li D, Zhan X, Garcia JGN, Tuder RM, Hassoun PM, Johns RA (2003) Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Cir Physiol 285:H938-H945
28. Gomberg-Maitland M, Tapson VF, Benza RL, McLaughlin VV, Krichman A, Widlitz AC, Barst RJ (2005) Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 172:1586-1589
29. Guerard P, Rakotoniaina Z, Goirand F, Rochette L, Dumas M, Lirussi F, Bardou M (2006) The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS. Naunyn-Schmiedeberg's Arch Pharmacol (in press)
30. Guignabert C, Izikki M, Tu LI, Li Z, Zadigue P, Barlier-Mur A-M, Hanoun N, Rodman D, Hamon M, Adnoy S, Eddahibi S (2006) Transgenic mice overexpressing 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 98:1323-1330
31. Hamelin BA, Turgeon J (1998) Hydrophilicity/lipophilicity relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 19:26-37
32. Hardziyenka M, Campian ME, de Bruin R, Michel MC, Tan HL (2006) Sequence of echocardiographic changes during the development of right ventricular failure in rats. J Am Soc Echocardiogr (in press)
33. 2) analogue, beraprost sodium, on a patient with primary pulmonary hypertension: a case report. Angiology 49:161-164
34. Hill NS, Warburton RR, Pietras L, Klinger JR (1997) Non-specific endothelin- receptor antagonists blunts monocrotaline-induced pulmonary hypertension in rats. J Appl Physiol 83:1209-1215
35. Hoeper MM, Schwarze M, Ehlerding S, Adler-Shuermeyer A, Spiekerkoetter E, Niedermeyer J, Hamm M, Fabel H (2000) Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 342:1866-1870
36. Horstman DJ, Frank DU, Rich GF (1998) Prolonged inhaled NO attenuates hypoxic, but not monocrotaline-induced pulmonary vascular remodeling in rats. Anesth Analg 86:74-81
37. Hughes RJ, Jais X, Bonderman D, Suntharalingam J, Humbert M, Lang I, Simmoneau G, Pepke-Zaba J (2006) The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J 26:138-143
38. Ikeda D, Tsujimo I, Ohira H, Itoh N, Kamgaki M, Ishimaru S, Sakaue S, Nishimura M (2005) Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension. J Cardiovasc Pharmacol 45:286-289
39. Inoue H, Yano K, Noto T, Takagi M, Ikeo T, Kikkawa (2002) Acute and chronic effects of T-1032, a novel selective phosphodiesterase type 5 inhibitor, on monocrotaline-induced pulmonary hypertension in rats. Biol Pharm Bull 25(11):1422-1426
40. Itoh T, Nagaya N, Fujii T, Iwase T, Nakanishi N, Hamada K, Kangawa K, Kimura H (2004) A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 169:34-38
41. Ivy DD, Parker TA, Ziegler JW, Galan HL, Kinsella JP, Tuder RM, Abman SH (1997) Prolonged endothelin A receptor blockade attenuates chronic pulmonary hypertension in the ovine fetus. J Clin Invest 99:1179-1186
42. Ivy DD, Le Cras TD, Horan MP, Abman S (1998) Increased lung prepoET-1 and decrease ETB-receptor gene expression in fetal pulmonary hypertension. Am J Physiol 274:L535-L541
43. A antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation 103:314-318
44. Jeffery TK, Wanstall JC (2001) Pulmonary vascular remodeling in hypoxic rats: effect of amlodipine, alone and with perindropil. Eur J Pharmacol 416:123-131
45. Kao PN (2005) Simvastatin treatment of pulmonary hypertension: an observational case series. Chest 127:1446-1452
46. Kataoka M, Nagaya N, Satoh T, Itoh T, Murakami S, Iwase T, Miyahara Y, Kyotani S, Sakai Y, Kangawa K, Ogawa S (2005) A long- acting prostacyclin antagonist with tromboxane inhibitory activity for pulmonary hypertension. Am J Respir Crit Care Med 172:1575-1580
47. Kim H, Yung GL, Marsh JJ, Konopka RG, Pedersen CA, Chiles PG, Morros TA, Channick RN (2000) Endothelin mediates pulmonary vascular remodeling in a canine model of chronic embolic pulmonary hypertension. Eur Resp J 15:640-648
48. Koh KK (2000) Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 47:648-657
49. Kwak B, Mulhaupt F, Myit S (2000) Statins as a new recognized type of immunomodulator. Nat Med 6:1399-1402
50. Ladha F, Bonnet S, Eaton F, Hashimoto K, Korbutt G, Thebaud B (2005) Sildenafil improves alveolar growth and pulmonary hypertension in hypoxia-induced lung injury. Am J Respir Crit Care Med 172:750-756
51. Lalich JJ, Merkow L (1961) Pulmonary arteritis produced in rats by feeding Crotolaria spectabilis. Lab Invest 10:744-750
52. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Philips JA III, Loyd JE, Nichols WC, Trembath RC (2000) Heterozygous germline mutation in BMPR2, encoding a TGF- beta receptor, cause familial primary pulmonary hypertension. The international PPH Consortium. Nat Genet 26:81-84
53. Levin DL, Heymann MA, Kitterman JA, Gregory GA, Phibbs RH, Rudolph AM (1976) Persistent pulmonary hypertension of the newborn infant. J Pediatr 89:626-630
54. Lopes AA, Maeda NY, Goncalves RC, Bydlowski S (2000) Endothelial cell dysfunction correlates differentially with survival in primary and secondary pulmonary hypertension. Am Heart J 139:618-623
55. Loscalzo J (1992) Endothelial dysfunction in pulmonary hypertension. N Engl J Med 27(2):117-119
56. Maiya S, Hislop AA, Flynn Y, Haworth SG (2006) Response to bosentan in children with pulmonary hypertension. Heart 92:664-670
57. Malik AB, van de Zee H (1977) Time course of pulmonary vascular response to microembolization. J Appl Physiol 43:51-58
58. Maruyama J, Maruyama K, Mitani Y, Kitabatake M, Yamauchi T, Miyasaka K (1997) Continuous low-dose NO inhalation does not prevent monocrotaline-induced pulmonary hypertension in rats. Am J Physiol 272:H517-H524
59. Mattocks AR (1968) Toxicity of pirrolizidine alkaloids. Nature 217:723-728
60. Mattocks AR (1986) Chemistry and toxicology of pyrrolizidine alkaloids. Academic, New York
61. McLaughlin VV, Rich S (1998) Pulmonary hypertension- advances in medical and surgical intervention. J Heart Lung Transplant 17:739-743
62. McLaughlin VV, Gentthner DE, Panella MM, Rich S (1998) Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338:273-277
63. Meyrick B, Read L (1978) The effect of continuous hypoxia on rat pulmonary arterial circulation: an ultra structural study. Lab Invest 38:188-200
64. Meyrick B, Read L (1980) Hypoxia- induced structural changes in the media and adventitia of rat hilar pulmonary artery and their regression. Am J Pathol 100:151-178
65. Mitani Y, Maruyama K, Sakurai M (1997) Prolonged administration of L- arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats. Circulation 96:689-697
66. Miyata M, Ueno M, Sekine H (1996) Protective effect of beraprost sodium, a stable prostacyclin analogue, in development of monocrotaline-induced pulmonary hypertension. J Cardiovasc Pharmacol 27:20-26
67. Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, Nishikibe M, Yano M, Yanaguchi I, Sugishita Y, Goto K (1993) Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alteration in rats with monocrotaline- induced pulmonary hypertension. Circ Res 73:887-897
68. Molteni A, Ward WF, Ts'ao CH, Solliday NH, Dunne M (1985) Monocrotaline-induced pulmonary fibrosis in rats: amelioration by captopril and penicillamine. Proc Soc Exp Biol Med 180:112-120
69. Morel OE, Buvry A, Le Corvoisier P, Tual L, Favret F, Leon-Velarde F, Crozatier B, Richalet JP (2003) Effects of nifedipine-induced pulmonary vasodilatation on cardiac receptors and protein kinaze C isoform in the chronically hypoxic rats. Eur J Physiol 446:356-364
70. Morin FC III (1989) Ligating the ductus arteriosus before birth causes persistent pulmonary hypertension in the newborn lamb. Pediatr Res 25:245-250
71. Murphy JD, Rabinovitch M, Goldstein JD, Reid LM (1981) The structural basis of persistent pulmonary hypertension of the newborn infant. J Pediatr 98:962-967
72. Naeije R, Melot CH, Mols P, Hallemans R (1982) Effects of vasodilators on hypoxic pulmonary vasoconstriction in normal man. Chest 82:404-410
73. Nagaya N, Yokoyama C, Kyotani S, Shimonishi M, Morishita R, Uematsu M, Nishikimi T, Nakanishi N, Ogihara T, Yamagishi M (2000) Gene transfer of human prostacyclin synthase ameliorates monocrotaline-induced pulmonary hypertension in rats. Circulation 102:2005-2012
74. Nakamoto T, Harasawa H, Akimot K, Hirata H, Kaneko H, Kaneko N, Sorimachi K (2005) Effects of olmesartan medoxomil as an angiotensin II-receptor blockers in chronic hypoxic rats. Eur J Pharmacol 528:43-51
75. Nguyen QT, Colombo F, Rouleau JL, Dupuis J, Calderone A (2000) LU135252, an endothelin (a) receptor antagonist did not prevent pulmonary vascular remodeling or lung fibrosis in a rat model of myocardial infarction. Br J Pharmacol 130: 1525-1530
76. Nishimura T, Faul JL, Berry GJ, Veve I, Kao PN, Pearl RG (2001) 40-0-(2-Hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 163:498-502
77. Nishimura T, Faul JL, Berry GJ, Vaszar LT, Qiu D, Pearl RG, Kao P (2002) Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 166:1403-1408
78. Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L, Qiu D, Benson G, Pearl RG, Kao PN (2003) Simvastatin rescue rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cell. Circulation 108:1640-1645
79. Nong Z, Stassen JM, Moons L, Collen D, Janssen S (1996) Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling. Circulation 94:1941-1947
80. Okada K, Bernstein ML, Zhang W, Schuster DP, Botney MD (1998) Angiotensin -converting enzyme inhibition delays pulmonary vascular neointimal formation. Am J Respir Crit Care Med 158:939-950
81. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W (1996) Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 124:820-824
82. Palevsky HI, Fishman AP (1990) Chronic cor pulmonale: etiology and management. JAMA 263:2347-2353
83. Pauvert O, Bonnet S, Rousseau E, Marthan R, Savineau JP (2004) Sildenafil alters calcium signaling and vascular tone in pulmonary arteries from chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 287:L577-L583
84. Pomeranze HD, Bhavsar A (2005) Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (viagra): a case report of seven cases. J Neurol Ophthalmo l25:9-13
85. Prie S, Leung TK, Cernacek P, Ryan JW, Dupuis J (1997) The orally active ET (A) receptor antagonist (+)-(S)-2-(4,6-dimethoxypyrimidin-2-yloxy)-3-methoxy- 3,3-dipheyl-propionic acid (LU135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. J Pharmacol Exp Ther 282:1312-1318
86. Reeve JT, Wagner WW Jr, McMurtry IF, Grover RF (1979) Physiological effects of high altitude on the pulmonary circulation. Int Rev Physiol 20:289-310
87. Reid MJ, Lame MW, Morin D, Wilson DW, Segall HJ (1998) Involvement of cytochrome P450 3A in the metabolism and covalent binding of 14C-monocrotaline in rat liver microsomes. J Biochem Tox 12:157-166
88. Rich S, McLaughlin VV (1999) The effect of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardio 34:1184-1187
89. Rich S, Kaufmann E, Levy PS (1992) The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327:76-81
90. Richalet JP, Gratadour P, Robach P, Pham I, Dechaux M, Joncquiert-Latarjet A, Mollard P, Brugniaux J, Cornolo J (2005) Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. Am J Respir Crit Care Med 171:275-281
91. Roberts JD, Chiche JD, Weimann J, Stedel W, Zapol WM, Bloch KD (2000) Nitric oxide inhalation decreases pulmonary artery remodeling in the injured lungs or rat pup. Circ Res 84:140-145
92. Rosenzweig EB, Wildlitz AD, Oran A, Claussen LR, Yung D, Abman SH, Morganti A, Barst RJ (2005) Effect on long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 16:697-704
93. Rossaint R, Falke KJ, Lopez FA, Slama K, Pison U, Zapol WM (1993) Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 328:399-405
94. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896-903
95. 2 analogue, beraprost, in primary and secondary pulmonary hypertension. Am J Cardiol 78:244-247
96. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermet L, Ermet M, Weissmann N, Rose F, Guenther A, Walmrath D, Seeger W, Grimminger F (2004) Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 169:39-45
97. Schermuly RT, Yilmaz H, Ghofrani HA, Woyda K, Pullamsetti S, Schulz A, Gessler T, Dumitrascu R, Weissmann N, Grimminger F, Seeger W (2005) Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension. Am J Respir Crit Care Med 172:358-363
98. Segall HJ, Wilson DW, Lame MW, Morin D, Winter CK (1991) Toxicology of plant and fungal compounds. In: Keeler RF, Tu AT (eds) Handbook of natural toxins, Vol 6, pp 3-26
99. Shelub I, van Grondelle A, McCullough R, Hofmeister S, Reeves JT (1984) A model of embolic chronic pulmonary hypertension in dog. J Appl Physiol 56(3):810-885
100. Simonneau G, Galie N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A (2004) Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43(12):5S-12S
101. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S, Garcia G, Parent F, Herve P, Simonneau G (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111(23):3105-3111
102. Stamler JS, Loh E, Roddy MA (1994) Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy human. Circulation 89:2035-2040
103. Stewart DJ, Levy RD, Cernacek P, Langleben D (1991) Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 114:464-469
104. Takahashi T, Kanda T, Imai S, Suzuki T, Kobayashi I, Nagai R (1996) Amlodipine inhibits the development of right ventricular hypertrophy and medial thickening of pulmonary arteries in a rate model of pulmonary hypertension. Res Commun Mol Path Pharmacol 91:17-32
105. Tantini B, Manes A, Fiumana E, Pignatti C, Guarnieri C, Zannoli R, Branzi A, Galie N (2005) Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 100:131-138
106. Tilton RG, Munsch CL, Sherwood SJ, Chen S, Chen Y, Wu C, Block N, Dixon RA, Brock TA (2000) Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET (A) receptor antagonist. Pulm Pharmacol Ther 13:87-97
107. Tozzi CA, Poiani GJ, Harangozo AM, Boyd CD, Riley DJ (1989) Pressure induced connective tissue synthesis in pulmonary artery segments in dependent on intact endothelium. J Clin Invest 84:1005-1012
108. Tuder RM, Groves B, Badesch DB, Voelkel NF (1994) Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesion of pulmonary hypertension. Am J Pathol 144(2):275-285
109. Ueno M, Miyauchi T, Sakai S, Yamauchi-Kohno R, Goto K, Yamaguchi I (2002) A combination of oral endothelin-A receptor analogue is superior to each drug alone in ameliorating pulmonary hypertension in rats. J Am Coll Cardiol 40:175-181
110. Van Suylen RJ, Smits JF, Daemen MJ (1998) Pulmonary artery remodeling differs in hypoxia- and monocrotaline-induced pulmonary hypertension. Am J Respir Crit Care Med 157:1423-1428
111. Voelkel NF, Tuder RM, Bridges J, Arend WP (1994) Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. Am J Respir Cell Mol Biol 11:664-675
112. Wanstall JC, Jeffery TK (1998) Recognition and management of pulmonary hypertension. Drugs 56:989-1007
113. Weimann J, Zink W, Schnabel PA, Jakob H, Gebhard MM, Martin E, Motsch J (1999) Selective vasodilatation by nitric oxide inhalation during sustained pulmonary hypertension following recurrent microembolism in pigs. J Critical Care 14(3):133-140
114. Weitzenblum E, Chauat A (2001) Hypoxic pulmonary hypertension in man: what minimum daily duration of hypoxaemia is required? Eur Respir J 18:251-253
115. Wilkins MR, Paul GA, Strange JW (2005) Sildenafil versus endothelin receptor antagonist fro pulmonary hypertension (SERAPH) study. Am J Respir Crit Care Med 171:1292-1297
116. Witt W, Muller B (1987) Antitrombotic profile of iloprost in experimental models of in vivo platelet aggregation and thrombosis. Adv Prostaglandin Thromboxane Leukot Res 17A:279-284
117. Yi ES, Kim H, Ahn H, Strother J, Morris T, Masliah E, Hansen LA, Park K, Friedman PJ (2000) Distribution of obstructive intima lesion and their cellular phenotypes in chronic pulmonary hypertension: a morphometric and immunohistochemical study. Am J Respir Crit Care Med 162:1577-1586
118. Zakheim RM, Mattioli L, Molteni A, Mullis KB, Bartley J (1975) Prevention of pulmonary vascular changes of chronic alveolar hypoxia by inhibition of angiotensin-II converting enzyme in rat. Lab Invest 33:57-61
119. Zhao L, Al-Tubuly R, Sebkhi A, Owji AA, Nunez DJR, Wilkins MR (1996) Angiotensin II receptor expression and inhibition in the chronically hypoxic rat lung. Br J Pharmacol 119:1217-1222
120. Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, Mirrakhimov MM, Aldashev A, Wilkins MR (2001) Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104:424-428